This respected group of retina specialists discusses biosimilar anti-VEGF therapies. Learn how they compare with their reference products, the process by which they gain FDA approval, their risks and benefits, and the policies that may influence incorporation into clinical practice.
This activity is supported by an unrestricted educational grant from Regeneron.

























